Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04WQT
|
|||
| Former ID |
DNCL002913
|
|||
| Drug Name |
RG7201
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 3 | [1] | |
| Company |
Roche
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/glucose cotransporter 2 (SLC5A4) | Target Info | Modulator | [1] |
| Reactome | Hexose transport | |||
| Na+-dependent glucose transporters | ||||
| Inositol transporters | ||||
| WikiPathways | NRF2 pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.